Sign in

CIK 0001512762 · Accelerated filer<br>Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273615821
Phone
(650) 649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Chief Scientific Officer acquired 31,250 shares (grant or award)
  3. 4 Grant or award Chief Financial Officer acquired 31,250 shares (grant or award)
  4. 4 Grant or award Chief Operating Officer acquired 31,250 shares (grant or award)
  5. 4 Shares withheld for taxes Chief Scientific Officer gave up 4,080 shares (to pay taxes)
  6. 4 Shares withheld for taxes Chief Financial Officer gave up 4,080 shares (to pay taxes)
  7. 4 Shares withheld for taxes Chief Operating Officer gave up 4,080 shares (to pay taxes)
  8. SC 13G Stake Amended Statement of Ownership
  9. 4 Derivatives Options or other derivatives
  10. 3 Insider Initial Statement of Ownership
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 8-K Event Executive or director change
  14. S-8 Other Securities Offered to Employees in Benefit Plans
  15. S-8 Other Securities Offered to Employees in Benefit Plans
  16. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $17.51 ($43,780)
  17. 4 Open-market sale Chief Scientific Officer sold 67,138 shares at an average $18.19 ($1,221,150)
  18. 4 Open-market sale Chief Operating Officer sold 8,791 shares at $18.42 ($161,896)
  19. 4 Open-market sale Chief Operating Officer sold 98,756 shares at an average $18.76 ($1,852,773)
  20. 4 Open-market sale Chief Operating Officer sold 22,770 shares at an average $17.72 ($403,510)

Page 20 of 47 · 923 filings